Outcomes, costs, and policy caution. A commentary on: the Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).
作者信息
Rosenheck Robert A
机构信息
Northeast Program Evaluation Center, Department of Veterans Affairs Connecticut Health Care System, West Haven, CT 06516, USA.
出版信息
Arch Gen Psychiatry. 2006 Oct;63(10):1074-6. doi: 10.1001/archpsyc.63.10.1074.
PMID:17015809
Abstract
摘要
Zotero 插件